State of Alaska Department of Revenue grew its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 1,205.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 159,645 shares of the biopharmaceutical company’s stock after acquiring an additional 147,415 shares during the period. State of Alaska Department of Revenue’s holdings in Bristol-Myers Squibb were worth $9,780,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also modified their holdings of BMY. Atlantic Trust LLC bought a new position in shares of Bristol-Myers Squibb during the 2nd quarter valued at about $111,000. Massey Quick Simon & CO. LLC raised its position in shares of Bristol-Myers Squibb by 523.5% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 1,492 shares in the last quarter. Blue Chip Partners Inc. raised its position in shares of Bristol-Myers Squibb by 0.7% during the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 15 shares in the last quarter. Horan Capital Advisors LLC. purchased a new stake in shares of Bristol-Myers Squibb during the 3rd quarter valued at about $122,000. Finally, BDO Wealth Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb during the 2nd quarter valued at about $123,000. 71.55% of the stock is owned by hedge funds and other institutional investors.
Shares of Bristol-Myers Squibb Co (NYSE BMY) opened at $66.68 on Wednesday. The firm has a market cap of $110,117.72, a P/E ratio of 22.41, a price-to-earnings-growth ratio of 2.07 and a beta of 0.98. Bristol-Myers Squibb Co has a one year low of $51.56 and a one year high of $70.05. The company has a quick ratio of 1.43, a current ratio of 1.55 and a debt-to-equity ratio of 0.59.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be issued a $0.40 dividend. The ex-dividend date of this dividend is Thursday, April 5th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.40%. Bristol-Myers Squibb’s dividend payout ratio is currently 271.19%.
In related news, Director Theodore R. Samuels II purchased 4,000 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was acquired at an average price of $62.30 per share, with a total value of $249,200.00. Following the completion of the acquisition, the director now owns 22,000 shares in the company, valued at approximately $1,370,600. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.23% of the company’s stock.
BMY has been the topic of several recent research reports. Vetr cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 target price on the stock. in a research report on Tuesday, January 16th. Citigroup set a $72.00 target price on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Tuesday, December 5th. Zacks Investment Research raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research report on Friday, January 19th. Credit Suisse Group set a $62.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Monday, January 22nd. Finally, BMO Capital Markets set a $49.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research report on Monday, December 11th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $66.30.
COPYRIGHT VIOLATION WARNING: This story was first reported by Week Herald and is the property of of Week Herald. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://weekherald.com/2018/03/14/state-of-alaska-department-of-revenue-buys-147415-shares-of-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.